Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kabra Drugs Ltd (BSE Scrip Code: 524322) has submitted a routine compliance filing informing BSE that it published the extract of its Unaudited Financial Results for the quarter ended June 30, 2025 in two newspapers: Free Press (English) and Navbharat (Hindi). This publication was carried out as mandated under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The letter is signed by Managing Director Nanjappan Aravind (DIN: 01895602) and dated August 23, 2025. No specific financial figures are disclosed in this particular submission — it only confirms that the newspaper advertisement compliance requirement has been fulfilled.
This is a routine regulatory disclosure with no material impact on the stock price or shareholders. It simply confirms the company met SEBI's newspaper publication requirement for its Q1 FY26 results. Investors seeking actual financial performance should refer to the detailed financial results filing rather than this compliance notice.